Federal Register / Vol. 74, No. 81 / Wednesday, April 29, 2009 / Notices 19565 

remains the same. The meeting is closed 

to the public. 

Dated: April 22, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–9857 Filed 4–28–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel. SRSP 

Conflicts. 

Date: June 11, 2009. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Melrose Hotel, 2430 Pennsylvania 

Ave., NW., Washington, DC 20037. 

Contact Person: Marina Broitman, PhD, 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Blvd., Room 6153, MSC 9608, 

Bethesda, MD 20892–9608. 301–402–8152. 

mbroitma@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

Dated: April 22, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–9860 Filed 4–28–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Dengue Tetravalent Vaccine 

Containing a Common 30 Nucleotide 

Deletion in the 3′-UTR of Dengue Types 

1,2,3, and 4 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services (HHS), is 

contemplating the grant of a an 

exclusive license to practice the 

following invention as embodied in the 

following patent applications: (1) E– 

120–2001/0, Whitehead et al., 

‘‘Development of Mutations Useful for 

Attenuating Dengue Viruses and 

Chimeric Dengue Viruses’’, Brazilian 

Patent Application PI0209943.8, filed 

May 22, 2002, (2) E–089–2002/0,1, 

Whitehead et al., ‘‘Dengue Tetravalent 

Vaccine Containing a Common 30 

Nucleotide Deletion in the 3′-UTR of 

Dengue Types 1,2,3, and 4, or Antigenic 

Chimeric Dengue Viruses 1,2,3, and 4’’, 

Brazilian Patent Application 

PI0309631–9, filed April 25, 2003, and 

(3) E–139–2006/0, Whitehead et al., 

‘‘Development of Dengue Vaccine 

Components’’, Brazilian Patent 

Application TBA, filed August 15, 2007 

to Fundacao Butantan, having a place of 

business in Sao Paulo, Brazil. The 

patent rights in this invention have been 

assigned to the United States of 

America. 

DATE: Only written comments and/or 

application for a license which are 

received by the NIH Office of 

Technology Transfer on or before May 

14, 2009 will be considered. 

ADDRESSES: Requests for a copy of the 

patent application, inquiries, comments 

and other materials relating to the 

contemplated license should be directed 

to: Peter Soukas, Office of Technology 

Transfer, National Institutes of Health, 

6011 Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; E-mail: 

ps193c@nih.gov; Telephone: (301) 435– 

4646; Facsimile: (301) 402–0220. 

SUPPLEMENTARY INFORMATION: The global 

prevalence of dengue has grown 

dramatically in recent decades. The 

disease is now endemic in more than 

100 countries in Africa, North and 

South America, the Eastern 

Mediterranean, Southeast Asia and the 

Western Pacific. Southeast Asia and the 

Western Pacific are most seriously 

affected. Before 1970 only nine 

countries had experienced Dengue 

Hemorrhagic Fever (DHF) epidemics, a 

number that had increased more than 

four-fold by 1995. WHO currently 

estimates there may be 50 million cases 

of dengue infection worldwide every 

year. 

The methods and compositions of this 

invention provide a means for 

prevention of dengue infection and 

dengue hemorrhagic fever (DHF) by 

immunization with attenuated, 

immunogenic viral vaccines against 

dengue. The vaccine is further described 

in Blaney JE et al., ‘‘Mutations which 

enhance the replication of dengue virus 

type 4 and an antigenic chimeric dengue 

virus type 2/4 vaccine candidate in Vero 

cells.’’ Vaccine. 2003 Oct 1;21(27– 

30):4317–27 and Whitehead SS et al., 

‘‘A live, attenuated dengue virus type 1 

vaccine candidate with a 30-nucleotide 

deletion in the 3′ untranslated region is 

highly attenuated and immunogenic in 

monkeys.’’ J. Virol. 2003 Jan;77(2):1653– 

7. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless, 

within 60 days from the date of this 

published Notice, NIH receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR 404.7. 

The field of use may be limited to live 

attenuated vaccines against dengue 

infections in humans. The Licensed 

Territory may be limited to Brazil. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: April 23, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–9853 Filed 4–28–09; 8:45 am] 

BILLING CODE 4140–01–P 


pwalker on PROD1PC71 with NOTICES